InvestorsHub Logo
Followers 35
Posts 1771
Boards Moderated 0
Alias Born 09/25/2012

Re: A deleted message

Sunday, 09/22/2019 8:32:30 PM

Sunday, September 22, 2019 8:32:30 PM

Post# of 108192
That's very easy to answer.

Because NEO and HoT are in the phase 1 portion of testing. With more immunogenicity data coming out in the 2nd half of 2019, pending results are good then they can find a partner.

As for the Lm tech in metastatic castration-resistant prostate cancer it is because the phase 2 survival data will be crucial. If survival , median overall survival, is improved over Xtandi and Zytiga/Erleada then Advaxis will 100% gain a partnership easily.

Any other questions you need answers to?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ADXS News